Many drugs increase ACE2 and COVID-19 (176 page review) - Dec 2020

A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor

Pharmacology & Therapeutics. online 1 Dec.
Murat Oz a Dietrich Ernst Lorke b c NadineKabbanid



COVID-19 treated by Vitamin D - studies, reports, videos

As of Aug 22, 2023, the VitaminDWiki COVID page had:  19 trial results,   37 meta-analyses and reviews,   Mortality studies   see related:   Governments,   HealthProblems,   Hospitals,  Dark Skins,   All 26 COVID risk factors are associated with low Vit D,   Fight COVID-19 with 50K Vit D weekly   Vaccines   Take lots of Vitamin D at first signs of COVID   166 COVID Clinical Trials using Vitamin D (Aug 2023)   Prevent a COVID death: 9 dollars of Vitamin D or 900,000 dollars of vaccine - Aug 2023
5 most-recently changed Virus entries

The study on this page is the 41st association in the above list

 Download the PDF from VitaminDWiki

The recent emergence of coronavirus disease-2019 (COVID-19) as a global pandemic has prompted scientists to address an urgent need for defining mechanisms of disease pathology and treatment. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19, employs angiotensin converting enzyme 2 (ACE2) as its primary target for cell surface attachment and likely entry into the host cell. Thus, understanding factors that may regulate the expression and function of ACE2 in the healthy and diseased body is critical for clinical intervention.
Over 66% of all adults in the United States are currently using a prescription drug and while earlier findings have focused on possible upregulation of ACE2 expression through the use of renin angiotensin system (RAS) inhibitors, mounting evidence suggests that various other widely administered drugs used in the treatment of

  • hypertension,
  • heart failure,
  • diabetes mellitus,
  • hyperlipidemias,
  • coagulation disorders, and
  • pulmonary disease

may also present a varied risk for COVID-19.
Specifically, we summarize mechanisms on how

  • heparin,
  • statins,
  • steroids and
  • phytochemicals,

besides their established therapeutic effects, may also interfere with SARS-CoV-2 viral entry into cells.
We also describe evidence on the effect of several vitamins, phytochemicals, and naturally occurring compounds on ACE2 expression and activity in various tissues and disease models.
This comprehensive review aims to provide a timely compendium on the potential impact of commonly prescribed drugs and pharmacologically active compounds on COVID-19 pathology and risk through regulation of ACE2 and RAS signaling.

3358 visitors, last modified 04 Jan, 2021,
Printer Friendly Follow this page for updates